An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1

AIM: Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non–small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in the USA and EU for advanced melanoma, NSCLC, and RC...

Descripción completa

Detalles Bibliográficos
Autores principales: Cogswell, John, Inzunza, H. David, Wu, Qiuyan, Feder, John N., Mintier, Gabe, Novotny, James, Cardona, Diana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250639/
https://www.ncbi.nlm.nih.gov/pubmed/27667773
http://dx.doi.org/10.1007/s40291-016-0237-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250639/
https://www.ncbi.nlm.nih.gov/pubmed/27667773
http://dx.doi.org/10.1007/s40291-016-0237-9

Ejemplares similares